Javascript must be enabled to continue!
Efficient Loading of cisplatin into Superabsorbent Polymer Microsphere in the treatment of hepatocellular carcinoma.
View through CrossRef
Background: Although Superabsorbent Polymer (SAP) microsphere has been useful in treatment of multiple and large hepatocellular carcinoma, efficient loading procedure of cisplatin onto SAP was not established. Loading efficiency of cisplatin was evaluated from the viewpoint of passive concentration gradient and ionic strength. Methods: To load cisplatin into SAP particle, 50mg of cisplatin powder was dissolved in three manners of aqueous solutions: (a) 50mg of cisplatin powder plus 35ml of warmed physiological saline solution (0.9%), (b) 5ml of physiological saline solution (0.9%) plus a half of solution (5ml) of the product made from 50mg of cisplatin powder in 10ml of iohexol 350mgI/ml, and (c) 10ml of iohexol 350mgI/ml plus 0.25ml of 10% NaCl solution Results: Cisplatin dissolved sufficiently in all the three methods. Average amounts of loaded cisplatin into SAP particles were 1.7mg in solution (a), 6.6mg in solution (b), and 11.8mg in solution (c). Since alteration of ionic strength in the method (c) significantly affect the extent of SAP swelling, addition of 0.25ml of 10% NaCl was unquestionably necessary. Release of cisplatin from SAP was evidently gradual, showing 83.1% after 6 hours in static elution experiment and 68.6% after 1 hour in dynamic elution experiment. Conclusions: Cisplatin-loaded SAP may act as a drug delivery system for treatment of liver cancer, and loading of cisplatin should be consciously performed considering cisplatin concentration and ionic strength. (225words)
Dr. Yashwant Research Labs Pvt. Ltd.
Title: Efficient Loading of cisplatin into Superabsorbent Polymer Microsphere in the treatment of hepatocellular carcinoma.
Description:
Background: Although Superabsorbent Polymer (SAP) microsphere has been useful in treatment of multiple and large hepatocellular carcinoma, efficient loading procedure of cisplatin onto SAP was not established.
Loading efficiency of cisplatin was evaluated from the viewpoint of passive concentration gradient and ionic strength.
Methods: To load cisplatin into SAP particle, 50mg of cisplatin powder was dissolved in three manners of aqueous solutions: (a) 50mg of cisplatin powder plus 35ml of warmed physiological saline solution (0.
9%), (b) 5ml of physiological saline solution (0.
9%) plus a half of solution (5ml) of the product made from 50mg of cisplatin powder in 10ml of iohexol 350mgI/ml, and (c) 10ml of iohexol 350mgI/ml plus 0.
25ml of 10% NaCl solution Results: Cisplatin dissolved sufficiently in all the three methods.
Average amounts of loaded cisplatin into SAP particles were 1.
7mg in solution (a), 6.
6mg in solution (b), and 11.
8mg in solution (c).
Since alteration of ionic strength in the method (c) significantly affect the extent of SAP swelling, addition of 0.
25ml of 10% NaCl was unquestionably necessary.
Release of cisplatin from SAP was evidently gradual, showing 83.
1% after 6 hours in static elution experiment and 68.
6% after 1 hour in dynamic elution experiment.
Conclusions: Cisplatin-loaded SAP may act as a drug delivery system for treatment of liver cancer, and loading of cisplatin should be consciously performed considering cisplatin concentration and ionic strength.
(225words).
Related Results
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract 1761: Dual inhibition of HSP27 and FAO as a novel therapeutic strategy for cisplatin-resistant ovarian cancer
Abstract
Cisplatin is the most commonly employed chemotherapeutic drug for ovarian cancer treatment. However, most ovarian cancer patients experience recurrent cispl...
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
RAD51C is a RAD51 paralog protein that mediates RAD51 filament formation on single-stranded DNA (ssDNA) in a canonical homologous recombination (HR) pathway. This step is vital for...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Nanogold and nanosilver hybrid polymer materials
Nanogold and nanosilver hybrid polymer materials
<p>Significant opportunities exist in both the scientific and industrial sectors for the development of new generation hybrid materials. These multifunctional hybrid material...
Astrocytes improve neuronal health after cisplatin treatment through mitochondrial transfer
Astrocytes improve neuronal health after cisplatin treatment through mitochondrial transfer
AbstractNeurodegenerative disorders, including chemotherapy-induced cognitive impairment, are associated with neuronal mitochondrial dysfunction. Cisplatin, a commonly used chemoth...
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
<div>Abstract<p><b>Purpose:</b> Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of t...
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Data from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
<div>Abstract<p><b>Purpose:</b> Ovarian cancer has the highest mortality rate of all female reproductive malignancies. Drug resistance is a major cause of t...

